ClinicalTrials.gg
CompletedNCT01724788Updated Feb 12, 2013

Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

A Phase 1 interventional study of FUROSEMIDE and FUROSEMIDE (HOE058) in Renal Failure, sponsored by Sanofi. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Sanofi.

Enrollment
12th of 12
12 · median 45
Started
2012
the only one that year
Phase 1
6 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Renal Insufficiency by Sanofi, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 1, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

  • To determine the absolute bioavailability of furosemide 500 mg (Lasix® Special) oral formulation in patients with chronic renal failure undergoing peritoneal dialysis.

Secondary Objectives:

  • To determine the pharmacokinetic profiles of furosemide 500 mg (Lasix® Special) oral formulation and 250 mg IV formulation
  • To compare the pharmacodynamic characteristics of furosemide 500 mg (Lasix® Special) oral formulation and 250 mg IV formulation
Read the detailed description
  • Screening: 7 to 10 days
  • Treatment period: 14 days (Period 1: 7 days; Period 2: 7 days)
  • End of study: 7 days after the last dosing,
  • Total duration from screening per subject: 22 to 25 days.
03

Conditions studied

  • Renal Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years old or older, with chronic renal failure undergoing peritoneal dialysis for at least 3 months.
  • Women of childbearing age should have a negative pregnancy test before administration of the study drug

Exclusion criteria

Exclusion criteria:

  • to furosemide, including:

    • to furosemide or to sulphonamide-derived drugs or to any ingredient in the formulation or component of the container.
    • below 5 mL/min
    • Glomerular filtration rate above 20 mL/min
    • Severe liver disease
    • Patients with renal failure accompanied by hepatic coma and precoma
    • Renal failure due to poisoning with nephrotoxic or hepatotoxic substances
    • Severe hyponatremia, hypokalemia, hypovolemia, dehydration or hypotension
    • Nursing women
  • Pregnancy
  • Treatment with any diuretic, which cannot be discontinued with the required before the first drug administration
  • Existence of any surgical or medical condition, which, in the judgment of the clinical investigator, might interfere with absorption, distribution, metabolism or excretion of drugs.
  • Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect patient safety and/or compliance.
  • Treatment with the following inhibitors of secretion at the renal level: clarithromycin, erythromycin, itraconazole, cyclosporin, ketoconazole, quinidine, and verapamil, which cannot be discontinued during the course of the study.

Interfering substance:Subjects must abstain from alcohol and beverages containing stimulating xanthine derivates (e.g. coffee and tea) during the entire study period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Furosemide PO - IV

    Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)

    Drug: FUROSEMIDE · Drug: FUROSEMIDE (HOE058)

  • Experimental
    Furosemide IV - PO

    IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)

    Drug: FUROSEMIDE · Drug: FUROSEMIDE (HOE058)

Interventions

  • Pharmaceutical form: Solution Route of administration: Intravenous

    Also known as: Furosemide Special Injection

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: Lasix® Special

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability (F) of a single 500-mg oral tablet

    Time frame: Day 1, 4, 8, 11

Secondary outcomes

  1. To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Cmax (maximum (peak) plasma drug concentration) after single dose administration

    Time frame: Day 1, 4, 8, 11

  2. To determine the pharmacokinetic parameters of furosemide (po and iv) measured by Tmax (time to reach peak or maximum concentration) following drug administration

    Time frame: Day 1, 4, 8, 11

  3. To determine the pharmacokinetic parameters of furosemide (po and iv) measured by AUCT 0-72 (area under curve from the time zero to 72h)

    Time frame: Day 1, 4, 8, 11

  4. To determine pharmacodynamic characteristics of furosemide (po and iv) including the excretion against time of urinary volume, urinary excretion, urea and creatinine

    Time frame: 0, 6, 12, 24 h

07

Study locations

1 site
  • Investigational Site Number 124002
    Montreal, H1T 2M4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2012
First posted
Nov 12, 2012
Start
Nov 2012
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01724788
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 12, 2012
Start date
Nov 2012
Primary completion
Jan 2013
Completion
Jan 2013
Last update
Feb 12, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion